A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).

被引：0
|
作者：
Karzai, Fatima H.
Madan, Ravi Amrit
Apolo, Andrea Borghese
Parnes, Howard L.
Wright, John Joseph
Trepel, Jane B.
Beatson, Melony A.
Harold, Nancy
Couvillon, Anna
Steinberg, Seth M.
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
机构：
[1] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[2] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Bethesda, MD 20892 USA
[4] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[5] NCI, Rockville, MD USA
[6] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5095
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC)
    Karzai, Fatima H.
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Philip M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [3] A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzal, Fatima
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Phillp M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Strauss, Julius
    Chun, Guinevere
    Couvillon, Anna
    Harold, Nancy
    Chen, Clara
    Dawson, Nancy Ann
    Apolo, Andrea Borghese
    Steinberg, Seth M.
    Trepel, Jane B.
    Wright, John Joseph
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C plus DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
    Al Harthy, Munjid
    Madan, Ravi Amrit
    Karzai, Fatima
    Petrylak, Daniel Peter
    Kim, Joseph W.
    Arlen, Philip M.
    Theoret, Marc Robert
    Marte, Jenn
    Bilusic, Marijo
    Couvillon, Anna
    Chun, Guinevere
    Owens, Helen
    Hankin, Amy
    Cordes, Lisa M.
    Figg, William Douglas
    Gulley, James L.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic castrate-resistant prostate cancer (mCRPC).
    Vankayala, Hema M.
    Heilbrun, Lance K.
    Dobson, Kimberlee
    Stark, Karri
    Li, Jing
    Smith, Daryn W.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
    Chi, K. N.
    De Bono, J. S.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer
    Madan, Ravi A.
    Karzai, Fatima H.
    Al Harthy, Munjid
    Petrylak, Daniel P.
    Kim, Joseph W.
    Arlen, Philip M.
    Rosner, Inger
    Theoret, Marc R.
    Cordes, Lisa
    Bilusic, Marijo
    Peer, Cody J.
    Dawson, Nancy A.
    Couvillon, Anna
    Hankin, Amy
    Williams, Moniquea
    Chun, Guin
    Owens, Helen
    Marte, Jennifer L.
    Lee, Min-Jung
    Tomita, Yusuke
    Yuno, Akira
    Trepel, Jane B.
    Lee, Sunmin
    Steinberg, Seth M.
    Gulley, James L.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2021, 127 (04) : 435 - 444
  • [9] A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Zurita, A.
    Shore, N. D.
    Kozloff, M. F.
    Ryan, C. W.
    Beer, T. M.
    Maneval, E. Chow
    Chen, I.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 287 - 287
  • [10] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
12345